Fischer Hearing Centre - Signs of hearing loss
Regina Watch
Recognizing signs of hearing loss is crucial for early intervention and treatment. Candace Fischer takes us through these tell-tale signs. #sponsoredcontent
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Globe and Mail
42 minutes ago
- Globe and Mail
Pfizer vs BMY: Which Oncology Drugmaker Is a Better Choice for Now?
Pharma/biotech giants Pfizer PFE and Bristol Myers BMY boast of a dominant position in the lucrative oncology space. Oncology or cancer is one of the most sought-after areas in the pharma/biotech space. As the world at large continues to grapple with a significant increase in the number of cancer patients, the market for cancer medicines is expected to grow. Pfizer is one of the largest and most successful drugmakers in the field of oncology. Oncology sales comprise around 25% of its total revenues. Oncology is a key therapeutic area of focus for Bristol Myers, which is developing and delivering transformational medicines in this space. Both drugmakers have strong footholds in their respective target markets, delivering consistent returns to shareholders. In such a scenario, choosing one stock over another can be challenging. Let us delve into their fundamentals, potential growth prospects, challenges and valuation levels to make a prudent choice. The Case for Pfizer Pfizer has an innovative oncology product portfolio of antibody-drug conjugates (ADCs), small molecules, bispecifics and other immunotherapies that treat a wide range of cancers, including certain types of breast cancer, genitourinary cancer and hematologic malignancies, as well as certain types of melanoma, gastrointestinal, gynecological and lung cancer. Approved drugs in the portfolio include Ibrance, Xtandi, Inlyta, Lorbrena, Bosulif, Braftovi, Mektovi, Orgovyx, Elrexfio and Talzenna. Among these, the breast cancer drug Ibrance is one of the top revenue generators. The acquisition of Seagen in December 2023 strengthened PFE's oncology portfolio by adding four ADCs — Adcetris, Padcev, Tukysa and Tivdak. This initiative boosted oncology sales in 2024 and the first quarter of 2025. Seagen also has some next-generation ADC candidates in its pipeline and their successful development should further strengthen its portfolio. PFE is working on the label expansion of many of its cancer drugs that should boost sales. Pfizer also has oncology biosimilars in its portfolio and markets six of them for cancer. Oncology biosimilars primarily include Retacrit, Ruxience, Zirabev, Trazimera and Nivestym. Pfizer is also advancing a robust pipeline of oncology candidates, with several entering late-stage development. By 2030, it expects to have eight or more blockbuster oncology medicines in its portfolio. Apart from oncology, Pfizer's portfolio has a variety of drugs and vaccines for diseases like COVID-19, inflammation & immunology diseases, rare diseases and migraine, among others. The Case for Bristol Myers BMY is focused on extending and strengthening its leadership in immuno-oncology (IO), as well as diversifying beyond IO. Leading IO drug Opdivo, approved for several cancer indications, drives its oncology franchise along with Yervoy and Opdualag. The FDA recently granted approval to Opdivo Qvantig (nivolumab and hyaluronidase-nvhy) injection for subcutaneous use. Per BMY, this new subcutaneous formulation of Opdivo should help extend the reach and impact of its immuno-oncology franchise to patients into the next decade. Reblozyl, approved for first-line MDS-associated anemia, continues to drive market share within the larger first-line ring sideroblasts negative population. The CAR-T cell therapy Breyanzi is approved to treat the broadest array of B-cell malignancies. BMY has also been active on the acquisition front to expand its oncology portfolio/pipeline. In 2024, BMY acquired Mirati, a commercial-stage targeted oncology company, obtaining the rights to commercialize lung cancer medicine Krazati and to further develop several clinical assets, including PRMT5 Inhibitor. Krazati, a KRAS inhibitor, is approved for second-line non-small cell lung cancer (NSCLC) and is in clinical development with a PD-1 inhibitor for first-line NSCLC. It is also FDA approved for advanced or metastatic KRAS-mutated colorectal cancer with cetuximab. In addition, PRMT5 Inhibitor is a potential first-in-class MTA-cooperative PRMT5 inhibitor, which is advancing to the next stage of development. The acquisition of RayzeBio, a leader in the field of radiopharmaceuticals for solid tumor oncology, provided BMY with RYZ101, a late-stage asset, an investigational new drug engine and in-house manufacturing capabilities. In 2022, BMY acquired Turning Point and added lead asset, repotrectinib, and other clinical and pre-clinical stage assets to its pipeline. Repotrectinib was approved by the FDA in November 2023 and is marketed under the brand name Augtyro. Augtyro, a kinase inhibitor, is indicated for the treatment of adult patients with locally advanced or metastatic ROS1-positive NSCLC. It is also intended for the treatment of adult and pediatric patients 12 years of age and older with solid tumors that have NTRK gene fusion, are locally advanced or metastatic or where surgical resection is likely to result in severe morbidity, and have progressed following treatment or have no satisfactory alternative therapy. Bristol Myers is also focused on developing drugs with presence in hematology, immunology, cardiovascular, neuroscience and other therapeutic areas. A Look at Estimates: PFE vs BMY The Zacks Consensus Estimate for PFE's 2025 sales implies a year-over-year decrease of 0.6%, and that for earnings per share (EPS) suggests a year-over-year decline of 1.61%. EPS estimates for 2025 and 2026 have moved north in the past 60 days. PFE's Estimate Movement The Zacks Consensus Estimate for BMY's 2025 sales implies a year-over-year decrease of 4.13% while that for EPS suggests an increase of 487.83%. The extraordinary EPS growth rate is attributed to an extremely low EPS figure in 2024 due to acquisition expenses. EPS estimates for both 2025 and 2026 have moved south in the past 60 days. BMY's Estimate Movement Price Performance and Valuation of PFE and BMY From a price-performance perspective, PFE has performed better than BMY so far this year. Shares of PFE have declined 6.8%, while those of BMY have lost 15.4%. The large-cap pharma industry has declined 0.3% in the said period. From a valuation standpoint, we use the P/E ratio of the large-cap pharma industry to compare these companies. Going by the same, PFE is slightly more expensive than BMY. PFE's shares currently trade at 7.77X forward earnings, higher than 7.22 for BMY. PFE and BMY's attractive dividend yield is a strong positive for investors. However, PFE's dividend yield of 7.2% is higher than BMY's 5.29%. Which Stock Is a Better Pick for Now? Large pharma/biotech companies are generally considered safe havens for investors interested in this sector. However, with both PFE and BMY stocks currently carrying a Zacks Rank #3 (Hold), choosing one over the other is a complex task. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here. PFE has a strong and diverse portfolio but faces challenges like declining sales of its COVID-19 products and U.S. Medicare Part D headwinds in 2025. Several of its key products face patent expirations. Nonetheless, drugs like Vyndaqel, Padcev and Eliquis, and newly acquired products should continue to drive top-line growth. BMY's efforts to revive the top line in the face of generic challenges for key drugs are commendable. However, we believe there is still time before the efforts reap harvest for the company. The outlook for 2025 indicates challenges as of now. Hence, PFE is a better pick at present (despite its slightly pricey valuation), primarily due to the diversity of its portfolio and higher dividend yield compared to BMY. Zacks Names #1 Semiconductor Stock It's only 1/9,000th the size of NVIDIA which skyrocketed more than +800% since we recommended it. NVIDIA is still strong, but our new top chip stock has much more room to boom. With strong earnings growth and an expanding customer base, it's positioned to feed the rampant demand for Artificial Intelligence, Machine Learning, and Internet of Things. Global semiconductor manufacturing is projected to explode from $452 billion in 2021 to $803 billion by 2028. See This Stock Now for Free >> Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Bristol Myers Squibb Company (BMY): Free Stock Analysis Report Pfizer Inc. (PFE): Free Stock Analysis Report
Globe and Mail
42 minutes ago
- Globe and Mail
Ibogaine by David Dardashti to Illuminate the Transformative Ibogaine Experience at Psychedelic Conference 2025
DENVER, CO - June 20, 2024 - Ibogaine by David Dardashti, a pioneer in holistic Ibogaine therapy, is proud to announce its prominent participation on Day 2 of the highly anticipated Psychedelic Conference 2025. David Dardashti and his team will offer individual descriptions of the unique Ibogaine experience, providing invaluable insights for each and every person at the conference seeking information regarding profound and lasting healing from addiction, trauma, and other mental health challenges. The core of the discussion will center on the therapeutic journey of Ibogaine. Patients describe the experience as a profound, introspective voyage through the past, present, and even potential future aspects of their lives. Unlike other therapies, Ibogaine often facilitates a unique perspective, allowing individuals to revisit significant life events and internalize them not from their own clouded emotional state, but from the detached, objective viewpoint of an outside observer. This remarkable shift in perspective enables deep understanding, reconciliation, and the ability to release long-held emotional burdens, fostering genuine personal growth and a renewed sense of purpose. Ibogaine by David Dardashti emphasizes highly individualized treatment protocols. The duration of an Ibogaine treatment varies, ranging from a focused 4-day experience to a comprehensive 21-day program, depending on the individual's specific needs, medical history, and the nature of their condition. Dosing is meticulously spread throughout the treatment period, starting with an initial transformative dose designed to interrupt cycles of dependence or deeply seated psychological patterns. This is often followed by carefully administered booster doses and, for longer programs, microdoses that support integration, neurogenesis, and sustained well-being in the weeks following the primary experience. This structured approach ensures both safety and maximal therapeutic benefit. "Ibogaine therapy, when administered with profound care and expertise, is not merely a detox; it is an awakening," says David Dardashti. "We guide individuals through a process that helps them confront their past, understand their present, and envision a healthier future. It's about empowering them to rewrite their narrative from a place of clarity and self-compassion, leading to truly sustainable transformation." Attendees of the Psychedelic Conference 2025 are invited to engage with Ibogaine by David Dardashti on Day 2 to gain a comprehensive understanding of this powerful plant medicine, its meticulous application, and the life-altering benefits it offers to those ready to embark on a journey of profound self-discovery and healing. About Ibogaine by David Dardashti: Ibogaine by David Dardashti is dedicated to providing safe, compassionate, and highly effective Ibogaine treatments. With a focus on individualized care, medical oversight, and comprehensive aftercare, the centers guide individuals towards sustainable recovery and improved mental well-being using the transformative properties of Ibogaine. About Psychedelic Conference 2025: The Psychedelic Conference 2025 is a leading international event bringing together researchers, practitioners, policymakers, and advocates to explore the latest advancements, therapeutic applications, and societal implications of psychedelic medicines.
CTV News
42 minutes ago
- CTV News
Quebec urges caution regarding tick, mosquito bites
From Jan. 1 to Oct. 26, 2024, 681 cases of Lyme disease were reported in Quebec. As summer begins, Quebec's Ministry of Health and Social Services is urging caution regarding tick and mosquito bites, which can transmit several diseases and viruses. Tick and mosquito populations are on the rise in several regions due to climate change, and the milder climate allows them to survive and thrive more easily. Quebec is reminding residents that ticks and mosquitoes can transmit Lyme disease, West Nile virus, and California Serogroup viruses, among others. The ministry notes that there are simple precautions people can take to protect themselves, such as using a DEET or icaridin-based mosquito repellent and wearing light-coloured, lightweight clothing. To protect yourself more specifically from ticks, prioritize walking on trails and avoid tall grass. If a tick attaches itself to your skin, remove it carefully, ideally within 24 hours. Lyme disease is the most common tick-borne disease in Quebec. As is the case elsewhere in the country, the numbers have increased significantly in recent years. In 2023, 2022, and 2021, there were 652, 586, and 709 cases, respectively. In comparison, there were 125 cases in 2014, 160 in 2015, and 177 in 2016. Lyme disease is transmitted by a tick bite carrying bacteria. It can also affect animals. In humans, the most common symptom of the disease is a red rash on the skin. Many people experience fatigue, fever, and body aches, but if the disease is not detected and treated quickly, the bacteria can spread through the bloodstream and cause other, more dire symptoms. If you suspect you may have been infected, Quebec recommends calling Info-Santé at 811. This report by The Canadian Press was first published in French on June 20, 2025.
